Pre-made Cibisatamab benchmark antibody (Bispecific mAb with Domain Crossover, anti-CEACAM5/CD66e;CD3E therapeutic antibody, Anti-CEA;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) researchCat No.: GMP-Bios-ab-104
Anti-CEACAM5/CD66e;CD3E therapeutic antibody (Pre-made Cibisatamab biosimilar,Bispecific mAb with Domain Crossover, Anti-CEA;T3E/TCRE/IMD18 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Cibisatamab, an investigational drug, is a bispecific antibody, which means it binds to two different proteins: one called CEACAM5 on the surface of some colorectal cancer cells and another on T cells called CD3.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Cibisatamab biosimilar, Bispecific mAb with Domain Crossover: Anti-CEACAM5;CD3E therapeutic antibody|
|Format||Bispecific mAb with Domain Crossover|
|Highest_Clin_Trial (Jan '20)||Phase-I/II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Non-small cell lung cancer;Colorectal cancer|
|Conditions Discontinued||Solid tumours|